Parkinson's Disease???

 

Presented by

 

John Slevin, MD, MBA

Professor of Neurology; Molecular and Biomedical Pharmacology

Vice Chair of Research, Department of Neurology

Director, Braden-Clark Movement Disorders Fellowship

University of Kentucky

 

Mario Yepez, MD

PGY3 Resident in Neurology

University of Kentucky

 

Tuesday, August 18, 2026

8:00 - 9:00 AM EDT

Zoom only: https://uky.zoom.us/j/81485627103

 

After this session, participants will be able to:

  1. Describe the clinical history and cardinal features of Parkinson's disease (PD)
  2. Define the relevant features that differentiate PD from PD+ syndromes
  3. Distinguish among neurodegenerative disorders that have parkinsonian characteristics

Disclosure of Financial Interest Summary

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

John Slevin, MD, faculty for this educational event, is a Clinical Investigator for NeuroDerm, Ltd., Intrance Medical Systems, Inc., Neuron23, Sumitomo Pharma America, Cerevance Beta, Inc., Appello Pharmaceuticals, Inc., and Novartis Pharma AG.

All of the relevant financial relationships listed for this individual have been mitigated.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Session date: 
08/18/2026 - 12:00am EDT to 10/18/2026 - 11:59pm EDT
  • 1.00 ACPE

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers. Course JA-UAN Number: JA0000312-0000-26-056-L01-P

  • 1.00 AMA PRA Category 1 Credit

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This Live activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity. 

  • 1.00 AMA PRA Category 1 Credit™ Participation

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This Live activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™ Participation. Learners should claim only credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC (UK Healthcare CECentral)

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour(s).

  • 1.00 IPCE

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

Please login or register to take this course.
Faculty List: 
Speaker(s)

John Slevin, MD, MBA

has a financial relationship (Grant Or Contract) with NeuroDerm, Ltd;.
has a financial relationship (Grant Or Contract) with Intrance Medical Systems, Inc;.
has a financial relationship (Grant Or Contract) with Neuron 23;.
has a financial relationship (Grant Or Contract) with Sumitomo Pharma America;.
has a financial relationship (Grant Or Contract) with Cerevance Beta, Inc;.
has a financial relationship (Grant Or Contract) with Appello Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Novartis Pharma AG;.

Mario Yepez

has no relevant financial relationships to disclose at this time.